Australian Clinical Labs Limited (ASX:ACL)

Market Cap	381.75M -37.8%
Revenue (ttm)	737.49M +1.3%
Net Income	26.31M -14.2%
EPS	0.14 -8.2%
Shares Out	188.98M
PE Ratio	14.33
Forward PE	11.56
Dividend	0.13 (6.19%)
Ex-Dividend Date	Mar 12, 2026

Volume	585,390
Average Volume	757,415
Open	2.030
Previous Close	2.020
Day's Range	2.030 - 2.080
52-Week Range	2.000 - 3.240
Beta	0.93
RSI	28.73
Earnings Date	Aug 26, 2026

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 4,700
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACL

Financial Performance

In fiscal year 2025, Australian Clinical Labs's revenue was 741.27 million, an increase of 6.45% compared to the previous year's 696.37 million. Earnings were 32.43 million, an increase of 35.50%.